Clinical validity of CTS5 for late recurrence in Chinese patients with early HR-positive breast cancer

被引：0
|
作者：
Xu, Junnnan [1 ]
Sun, Tao [1 ]
机构：
[1] Liaoning Canc Hosp & Inst, Shenyang, Peoples R China
来源：
CANCER RESEARCH | 2020年 / 80卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS19-P2-11-18
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2-11-18
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Everolimus combined with endocrine therapy in advanced HR-positive, HER2-negative Chinese breast cancer patients: A retrospective study.
    Shen, Xia-Bo
    Li, Guang-Liang
    Zheng, Ya-Bing
    Chen, Zhan-Hong
    Cao, Wen-Ming
    Shao, Xi-Ying
    Wang, Xiao-Jia
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [42] A real-world US study of recurrence risks using combined clinicopathological features in HR-positive, HER2-negative early breast cancer
    Sheffield, Kristin M.
    Peachey, Jessica R.
    Method, Michael
    Grimes, Brenda R.
    Brown, Jacqueline
    Saverno, Kim
    Sugihara, Tomoko
    Cui, Zhanglin Lin
    Lee, Kimberley T.
    FUTURE ONCOLOGY, 2022, 18 (21) : 2667 - 2682
  • [43] Predictive performance of breast cancer index (BCI) and clinical treatment score post-5 years (CTS5) in the IDEAL study.
    Liefers, Gerrit-Jan
    Noordhoek, Iris
    Putter, Hein
    Wong, Jenna
    Siuliukina, Natalia
    Zhang, Yi
    Kranenbarg, Elma Meershoek-Klein
    Duijm-de Carpentier, Marjolijn
    Van De Velde, Cornelis J. H.
    Schnabel, Catherine A.
    Treuner, Kai
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [44] EU-Approval for Ibrance for Therapy of Patients with HR-positive/HER2-negative Breast Cancer
    Janik, Achim
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 (1-2) : 67 - 67
  • [45] Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancer
    Shikata, Shohei
    Murata, Takeshi
    Yoshida, Masayuki
    Hashiguchi, Hiromi
    Yoshii, Yukiko
    Ogawa, Ayumi
    Watase, Chikashi
    Shiino, Sho
    Sugino, Hirokazu
    Jimbo, Kenjiro
    Maeshima, Akiko
    Iwamoto, Eriko
    Takayama, Shin
    Suto, Akihiko
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [46] Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancer
    Shohei Shikata
    Takeshi Murata
    Masayuki Yoshida
    Hiromi Hashiguchi
    Yukiko Yoshii
    Ayumi Ogawa
    Chikashi Watase
    Sho Shiino
    Hirokazu Sugino
    Kenjiro Jimbo
    Akiko Maeshima
    Eriko Iwamoto
    Shin Takayama
    Akihiko Suto
    Scientific Reports, 13
  • [47] Validation of Clinical Treatment Score post-5 years (CTS5) risk stratification in premenopausal breast cancer patients and Ki-67 labelling index
    Lee, Janghee
    Cha, Chihwan
    Ahn, Sung Gwe
    Kim, Dooreh
    Park, Soeun
    Bae, Soong June
    Kim, Jeeye
    Park, Hyung Seok
    Park, Seho
    Kim, Seung Il
    Park, Byeong-Woo
    Jeong, Joon
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [48] Factors predictive of response to neo-adjuvant hormone therapy in elderly patients with HR-positive breast cancer
    Zoubir, Mustapha
    Andre, Fabrice
    Rouzier, Roman
    Conforti, Rosa
    Garbay, Jean-Remi
    Spielmann, Marc
    Mathieu, Marie-Christine
    Vielh, Philippe
    Marsiglia, Hugo
    Delaloge, Suzette
    ANNALS OF ONCOLOGY, 2006, 17 : 159 - 159
  • [49] Validation of Clinical Treatment Score post-5 years (CTS5) risk stratification in premenopausal breast cancer patients and Ki-67 labelling index
    Janghee Lee
    Chihwan Cha
    Sung Gwe Ahn
    Dooreh Kim
    Soeun Park
    Soong June Bae
    Jeeye Kim
    Hyung Seok Park
    Seho Park
    Seung Il Kim
    Byeong-Woo Park
    Joon Jeong
    Scientific Reports, 10
  • [50] Palbociclib: First CDK4/6 Inhibitor in Clinical Practice for the Treatment of Advanced HR-Positive Breast Cancer
    Ettl, Johannes
    BREAST CARE, 2016, 11 (03) : 174 - 176
12345